Table 1 Clinical and demographical characteristics of the RA patient cohort
All n = 11 | EULAR response | ||
|---|---|---|---|
Good and moderate, n = 8 | No response, n = 3 | ||
Female, n (%) | 8 (72.7) | 5 (62.5) | 3 (100) |
Age (years) | 60.3 (7.1) | 60.3 (7.9) | 61 (6.9) |
Disease duration (years) | 17.0 (10.2) | 18.4 (10.6) | 13.4 (11.3) |
Follow-up (years) | 2.6 (1.9) | 3.6 (1.6) | 0.7 (0.8) |
DAS28ESR 3v (0 week) | 5.3 (1.6) | 5.95 (1.4) | 5.90 (1.8) |
DAS28ESR 3v (20 weeks) | 4.2 (1.7) | 3.51 (1.3) | 5.90 (1.9) |
RF positive (%) | 6 (54.5) | 5 (62.5) | 2 (66) |
ACPA positive (%) | 10 (90.1) | 7 (87.5) | 3 (100) |
Synovial pattern | |||
Lymphoid (%) | 7 (63.6) | 6 (75) | 1 (33.3) |
Myeloid (%) | 4 (36.3) | 2 (25) | 2 (66.6) |
Fibroid (%) | 0 | 0 | 0 |